Applicability of botulinum toxin type A in paediatric neurogenic bladder management

Purpose of review The purpose of this article is to provide an overview about the applicability of botulinum toxin type A (BTX-A) in paediatric neurogenic bladder based on the recently published literature combined with hypothetical notes and future perspectives. Recent findings The indications, clinical outcomes, urodynamic outcome parameters and cost-effectiveness are presented from recent publications. Also, alternative routes of application of BTX-A in the bladder are discussed as well as the influence of BTX-A on conservative and invasive treatment. Summary Intradetrusor BTX-A injections for neurogenic bladder dysfunction are effective in resolving both urinary incontinence and improving urodynamic parameters in most children with a sustained response at repeated injections. In low-compliance bladders, however, if no response is seen after initial BTX-A injection, repeated injections seem to be unnecessary. Because general anaesthesia is mandatory for BTX-A injections in children, alternative routes of application have been investigated such as intravesical installation, electromotive drug application and liposomal drug delivery; however, no definite results have been found in a paediatric clinical setting.

[1]  I. bonan,et al.  Outcomes of intra‐detrusor injections of botulinum toxin in patients with spina bifida: A systematic review , 2016, Neurourology and urodynamics.

[2]  P. Tyagi,et al.  Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. , 2016, The Journal of urology.

[3]  J. Abbott,et al.  Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children. , 2016, Journal of pediatric urology.

[4]  P. Reddy,et al.  Botulinum toxin injection in the pediatric population with medically refractory neuropathic bladder. , 2016, Journal of pediatric urology.

[5]  E. Shreck,et al.  Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA , 2016, Current Urology Reports.

[6]  M. Chancellor,et al.  Bladder Uptake of Liposomes after Intravesical Administration Occurs by Endocytosis , 2015, PloS one.

[7]  I. Yağmur,et al.  Botulinum injection is useless on fibrotic neuropathic bladders. , 2015, Journal of pediatric urology.

[8]  D. Gultyaev,et al.  Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX®) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective , 2014, PharmacoEconomics.

[9]  M. Chancellor,et al.  Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. , 2014, The Journal of urology.

[10]  S. Taskinen,et al.  Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder. , 2014, Journal of pediatric urology.

[11]  R. Dmochowski,et al.  Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States. , 2013, Clinical therapeutics.

[12]  Ş. Çetinel,et al.  Intradetrusor botulinum neurotoxin A (BoNT‐A) injections decrease bladder fibrosis secondary to partial urethral obstruction in the male rat model , 2012, Neurourology and urodynamics.

[13]  S. Tuncer,et al.  The effect of surgical and chemical denervation on ischaemia/reperfusion injury of skeletal muscle. , 2012, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[14]  M. Yeh,et al.  Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy , 2011, International journal of nanomedicine.

[15]  A. Amelink,et al.  Changes in bladder wall blood oxygen saturation in the overactive obstructed bladder. , 2011, The Journal of urology.

[16]  H. Ahmadi,et al.  Intravesical electromotive botulinum toxin type A administration: part I--Experimental study. , 2011, Urology.

[17]  Y. Liu,et al.  Botulinum Toxin Type A Inhibits Connective Tissue Growth Factor Expression in Fibroblasts Derived From Hypertrophic Scar , 2011, Aesthetic Plastic Surgery.

[18]  S. Bazargan-Hejazi,et al.  Intravesical electromotive botulinum toxin type A administration--part II: Clinical application. , 2011, Urology.

[19]  J. Krhut,et al.  Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial , 2011, International Urology and Nephrology.

[20]  R. Banerjee,et al.  Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[21]  P. Habibollahi,et al.  Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods. , 2010, Urology.

[22]  J. Frevert Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture® , 2010, Drugs in R&D.

[23]  Byung-Joo Lee,et al.  Effect of Botulinum Toxin Type A on a Rat Surgical Wound Model , 2009, Clinical and experimental otorhinolaryngology.

[24]  M. Chancellor,et al.  New frontiers in intravesical therapies and drug delivery. , 2006, European urology.

[25]  P. Dik,et al.  Early start to therapy preserves kidney function in spina bifida patients. , 2006 .

[26]  I. Tuğlu,et al.  The effects of botulinum-A toxin on bladder function and histology in spinal cord injured rats: is there any difference between early and late application? , 2005, The Journal of urology.

[27]  G. Somogyi,et al.  In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. , 2005, Urology.

[28]  N. Kinukawa,et al.  Risk factors for febrile urinary tract infection in children with myelodysplasia treated by clean intermittent catheterization , 2004, International journal of urology : official journal of the Japanese Urological Association.

[29]  A. Brading,et al.  Effects of metabolic stress and ischaemia on the bladder, and the relationship with bladder overactivity , 2004, Scandinavian journal of urology and nephrology. Supplementum.

[30]  T. Michael,et al.  Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. , 2002, Urology.

[31]  T. Schlager,et al.  Effect of a single-use sterile catheter for each void on the frequency of bacteriuria in children with neurogenic bladder on intermittent catheterization for bladder emptying. , 2001, Pediatrics.

[32]  D. Schmid,et al.  Treatment of neurogenic incontinence with botulinum toxin A. , 2000, The New England journal of medicine.

[33]  S. Bauer,et al.  Prognostic value of urodynamic testing in myelodysplastic patients. , 1981, The Journal of urology.

[34]  J. Lorber,et al.  Results of Treatment of Myelomeningocele , 1971, Developmental medicine and child neurology.